Serial Postoperative Circulating Tumor DNA Assessment Has Strong Prognostic Value During Long-Term Follow-Up in Patients With Breast Cancer.
Jacqueline A ShawKaren PageEvie WrenElza C de BruinEkaterina KalashnikovaRobert HastingsRob McEwenEddie ZhangMarc WadsleyEmmanuel AcheampongDerrick RennerKelly L T GleasonBana AmbasagerDaniel StetsonDaniel Fernandez-GarciaDavid GutteryRebecca C AllsoppAngel RodriguezBernhard ZimmermannHimanshu SethiAlexey AleshinMinetta C LiuCathy J RichardsJustin StebbingSimak AliFarah RehmanSusan CleatorLaura KennySamreen AhmedAnne C ArmstrongRaoul Charles CoombesPublished in: JCO precision oncology (2024)
Serial postoperative ctDNA assessment has strong prognostic value, provides a potential window for earlier therapeutic intervention, and may enable more effective monitoring than current clinical tests such as cancer antigen 15-3. Our study provides evidence that those with serially negative ctDNA tests have superior clinical outcomes, providing reassurance to patients with breast cancer. For select cases with HR+ disease, decisions about treatment management might require serial monitoring despite the ctDNA-positive result.